|
WO2020046767A1
|
|
Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors
|
|
WO2018057938A1
|
|
Comprehensive system for collecting, processing, processing and analyzing cell free nucleic acids in urine
|
|
WO2017201331A2
|
|
Oligonucleotide sequences for detection of low abundance target sequences and kits thereof
|
|
WO2017165869A1
|
|
Evaluaton of transgenes of genetically modified cells in bodily fluids
|
|
US2018087114A1
|
|
Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluid
|
|
US2016115556A1
|
|
Detecting mutations in disease over time
|
|
WO2015187512A1
|
|
Monitoring treatment of histiocytosis with vemurafenib and dabrafenib
|
|
EP3134524A1
|
|
Concentrating nucleic acids in urine
|
|
CN105283555A
|
|
Synthesis and enrichment of nucleic acid sequences
|
|
WO2015073163A2
|
|
Synthesis and enrichment of nucleic acid sequences
|
|
EP2951321A2
|
|
Synthesis and enrichment of nucleic acid sequences
|
|
AU2014336987A1
|
|
Detecting mutations in disease over time
|
|
US2015132256A1
|
|
Detecting and monitoring mutations in histiocytosis
|
|
WO2015058175A2
|
|
Detecting and monitoring mutations in histiocytosis
|
|
CN105229176A
|
|
The detection of urine amplifying nucleic acid
|
|
US2015376725A1
|
|
HPV Detection in Urine
|
|
AU2012329042A1
|
|
Methods of detecting BRAF mutations in cancer
|
|
EP2761299A1
|
|
Mutations in sf3b1 and chronic lymphocytic leukemia
|
|
AU2009308943A1
|
|
A genetic marker for detection of human papillomavirus
|
|
EP2853601A1
|
|
Methods for PCR-based detection of "ultra short" nucleic acid sequences
|
